Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam C Berger

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
American Journal of Clinical Oncology|January 28, 2020
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical TrialRoss A Abrams, Kathryn A Winter, Howard Safran, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Treatment and Research Communications|September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trialSpencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Annals of Surgery|November 17, 2020
The Influence of Intraoperative Blood Loss on Fistula Development Following PancreatoduodenectomyMaxwell T Trudeau, Fabio Casciani, Laura Maggino, et al.
Surgery|May 1, 2021
The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysisFabio Casciani, Maxwell T Trudeau, Horacio J Asbun, et al.
JAMA Surgery|May 30, 2019
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary CarcinomaBrett L Ecker, Charles M Vollmer, Stephen W Behrman, et al.
Surgery|January 2, 2021
Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula developmentFabio Casciani, Maxwell T Trudeau, Horacio J Asbun, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
American Journal of Clinical Oncology|January 28, 2020
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical TrialRoss A Abrams, Kathryn A Winter, Howard Safran, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Treatment and Research Communications|September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trialSpencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Annals of Surgery|November 17, 2020
The Influence of Intraoperative Blood Loss on Fistula Development Following PancreatoduodenectomyMaxwell T Trudeau, Fabio Casciani, Laura Maggino, et al.
Surgery|May 1, 2021
The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysisFabio Casciani, Maxwell T Trudeau, Horacio J Asbun, et al.
JAMA Surgery|May 30, 2019
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary CarcinomaBrett L Ecker, Charles M Vollmer, Stephen W Behrman, et al.
Surgery|January 2, 2021
Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula developmentFabio Casciani, Maxwell T Trudeau, Horacio J Asbun, et al.
Pageof 14